Blastic plasmacytoid dendritic cell neoplasm

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Blastic plasmacytoid dendritic cell neoplasm
File:PMC4314974 OL-09-03-1388-g02.png
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Skin lesions, fever, fatigue, lymphadenopathy
Complications	Leukemia, bone marrow failure
Onset	Typically in adults, median age around 60
Duration	Chronic
Types	N/A
Causes	Unknown
Risks	Possible genetic predisposition
Diagnosis	Biopsy, immunophenotyping, flow cytometry
Differential diagnosis	Acute myeloid leukemia, cutaneous T-cell lymphoma
Prevention	N/A
Treatment	Chemotherapy, stem cell transplantation
Medication	N/A
Prognosis	Poor, median survival less than 2 years
Frequency	Rare
Deaths	N/A

Blastic Plasmacytoid Dendritic Cell Neoplasm Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the proliferation of plasmacytoid dendritic cells. It primarily affects the skin, bone marrow, and lymph nodes.

Clinical Presentation

Patients with BPDCN often present with skin lesions, which may appear as bruise-like patches, nodules, or plaques. These lesions are typically purple or red and can occur anywhere on the body. In addition to skin involvement, BPDCN can affect the bone marrow, leading to cytopenias, and the lymph nodes, causing lymphadenopathy.

Pathophysiology

BPDCN arises from plasmacytoid dendritic cells, which are a type of immune cell involved in the production of interferon and the activation of other immune cells. The neoplastic cells in BPDCN express markers such as CD4, CD56, and CD123, which are used in the diagnosis of the disease.

Diagnosis

The diagnosis of BPDCN is based on a combination of clinical presentation, histopathological examination, and immunophenotyping. Skin biopsies, bone marrow aspirates, and lymph node biopsies are commonly used to obtain tissue samples for analysis. Immunohistochemistry is employed to detect the characteristic markers of BPDCN.

Treatment

Treatment options for BPDCN include chemotherapy, targeted therapy, and hematopoietic stem cell transplantation. Traditional chemotherapy regimens used for acute leukemia may be employed, but newer targeted therapies, such as tagraxofusp, have shown promise in treating BPDCN. Allogeneic stem cell transplantation is considered in eligible patients to achieve long-term remission.

Prognosis

The prognosis for BPDCN is generally poor due to its aggressive nature and high rate of relapse. Early diagnosis and treatment are crucial for improving outcomes. The development of targeted therapies has provided new hope for patients with this challenging disease.

See also

• Hematologic malignancy
• Plasmacytoid dendritic cell
• Acute leukemia
• Immunophenotyping
• Hematopoietic stem cell transplantation